Galiximab

Identification

Name
Galiximab
Accession Number
DB04901
Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Description

Galiximab is a chimeric monoclonal antibody which is used as an immunosuppressive drug.

Protein structure
Db04901
Protein chemical formula
Not Available
Protein average weight
Not Available
Sequences
Not Available
Synonyms
  • Anti-CD80 monoclonal antibody
External IDs
IDEC 114 / IDEC-114
International/Other Brands
GVAX
Categories
UNII
S9OX9692ZB
CAS number
357613-77-5

Pharmacology

Indication

Investigated for use/treatment in lymphoma (non-hodgkin's), psoriasis and psoriatic disorders, bone metastases, multiple myeloma, prostate cancer, and rheumatoid arthritis.

Pharmacodynamics

Galiximab is a monoclonal antibody that is being studied in the treatment of follicular non-Hodgkin lymphoma. Monoclonal antibodies are made in the laboratory and can locate and bind to cancer cells. Galiximab binds to the protein CD80, which is found on certain normal and cancerous white blood cells.

Mechanism of action

Galiximab, an IgG(1) anti-CD80 antibody, binds to CD80, a costimulatory molecule involved in T-cell activation. Reduction in lesional, activated T cells induces improvement in psoriatic plaques.

TargetActionsOrganism
UT-lymphocyte activation antigen CD80Not AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life

13 to 24 days

Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Galiximab.
AbituzumabThe risk or severity of adverse effects can be increased when Galiximab is combined with Abituzumab.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Galiximab.
AdecatumumabThe risk or severity of adverse effects can be increased when Galiximab is combined with Adecatumumab.
AducanumabThe risk or severity of adverse effects can be increased when Galiximab is combined with Aducanumab.
AfelimomabThe risk or severity of adverse effects can be increased when Galiximab is combined with Afelimomab.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Galiximab.
AlirocumabThe risk or severity of adverse effects can be increased when Galiximab is combined with Alirocumab.
AmatuximabThe risk or severity of adverse effects can be increased when Galiximab is combined with Amatuximab.
AMG 108The risk or severity of adverse effects can be increased when Galiximab is combined with AMG 108.
Food Interactions
Not Available

References

General References
  1. Czuczman MS, Thall A, Witzig TE, Vose JM, Younes A, Emmanouilides C, Miller TP, Moore JO, Leonard JP, Gordon LI, Sweetenham J, Alkuzweny B, Finucane DM, Leigh BR: Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma. J Clin Oncol. 2005 Jul 1;23(19):4390-8. [PubMed:15994148]
  2. Leonard JP, Friedberg JW, Younes A, Fisher D, Gordon LI, Moore J, Czuczman M, Miller T, Stiff P, Cheson BD, Forero-Torres A, Chieffo N, McKinney B, Finucane D, Molina A: A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma. Ann Oncol. 2007 Jul;18(7):1216-23. Epub 2007 Apr 29. [PubMed:17470451]
  3. Link [Link]
External Links
KEGG Drug
D04295
PubChem Substance
347909843
Wikipedia
Galiximab

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0RecruitingTreatmentMalignant Neoplasm of Pancreas1
1Active Not RecruitingTreatmentAlveolar Soft Part Sarcoma (ASPS) / Clear Cell Sarcoma of Soft Tissue / Melanoma / Renal Cell Adenocarcinoma1
1Active Not RecruitingTreatmentMetastatic Colorectal Cancers1
1RecruitingPreventionColorectal Cancers1
1TerminatedTreatmentNon-Hodgkin's Lymphoma (NHL)1
1TerminatedTreatmentProstate Cancer1
1, 2Active Not RecruitingTreatmentProstate Cancer Adenocarcinoma in Situ1
1, 2CompletedTreatmentMultiple Myeloma (MM) / Multiple Myeloma and Plasma Cell Neoplasm1
1, 2CompletedTreatmentNon-Hodgkin's Lymphoma (NHL)2
2Active Not RecruitingTreatmentMetastatic Colorectal Cancers1
2Active Not RecruitingTreatmentPreviously Treated Metastatic Adenocarcinoma of the Pancreas1
2CompletedTreatment2nd-line, 3rd-line and Greater Metastatic Pancreatic Cancer1
2CompletedTreatmentMalignant Lymphomas2
2CompletedTreatmentMalignant Neoplasm of Pancreas1
2CompletedTreatmentMalignant Neoplasm of Pancreas / Pancreatic Cancer Metastatic1
2RecruitingTreatmentChronic Myelomonocytic Leukemia / Leukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndrome1
2RecruitingTreatmentMalignant Neoplasm of Pancreas1
2RecruitingTreatmentPancreatic Adenocarcinoma Metastatic1
2SuspendedTreatmentPancreatic Adenocarcinoma Metastatic1
3RecruitingTreatmentInfantile Hemangiomas1
Not AvailableUnknown StatusPreventionTransplantation, Renal1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Liquid
Experimental Properties
Not Available

Taxonomy

Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Virus receptor activity
Specific Function
Involved in the costimulatory signal essential for T-lymphocyte activation. T-cell proliferation and cytokine production is induced by the binding of CD28, binding to CTLA-4 has opposite effects an...
Gene Name
CD80
Uniprot ID
P33681
Uniprot Name
T-lymphocyte activation antigen CD80
Molecular Weight
33047.625 Da
References
  1. Gottlieb AB, Kang S, Linden KG, Lebwohl M, Menter A, Abdulghani AA, Goldfarb M, Chieffo N, Totoritis MC: Evaluation of safety and clinical activity of multiple doses of the anti-CD80 monoclonal antibody, galiximab, in patients with moderate to severe plaque psoriasis. Clin Immunol. 2004 Apr;111(1):28-37. [PubMed:15093549]
  2. Czuczman MS, Thall A, Witzig TE, Vose JM, Younes A, Emmanouilides C, Miller TP, Moore JO, Leonard JP, Gordon LI, Sweetenham J, Alkuzweny B, Finucane DM, Leigh BR: Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma. J Clin Oncol. 2005 Jul 1;23(19):4390-8. [PubMed:15994148]
  3. Leonard JP, Friedberg JW, Younes A, Fisher D, Gordon LI, Moore J, Czuczman M, Miller T, Stiff P, Cheson BD, Forero-Torres A, Chieffo N, McKinney B, Finucane D, Molina A: A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma. Ann Oncol. 2007 Jul;18(7):1216-23. Epub 2007 Apr 29. [PubMed:17470451]

Drug created on October 21, 2007 16:23 / Updated on November 02, 2018 06:07